Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Common Equity (2018 - 2025)

Historic Common Equity for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $49.7 billion.

  • Takeda Pharmaceutical's Common Equity rose 177.6% to $49.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $49.7 billion, marking a year-over-year increase of 177.6%. This contributed to the annual value of $45.5 billion for FY2025, which is 972.5% down from last year.
  • Per Takeda Pharmaceutical's latest filing, its Common Equity stood at $49.7 billion for Q4 2025, which was up 177.6% from $48.4 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Common Equity high stood at $50.5 billion for Q2 2023, and its period low was $43.7 billion during Q4 2022.
  • Its 5-year average for Common Equity is $48.1 billion, with a median of $48.6 billion in 2022.
  • In the last 5 years, Takeda Pharmaceutical's Common Equity surged by 1264.88% in 2021 and then plummeted by 737.72% in 2025.
  • Takeda Pharmaceutical's Common Equity (Quarter) stood at $46.9 billion in 2021, then dropped by 6.79% to $43.7 billion in 2022, then increased by 4.34% to $45.6 billion in 2023, then rose by 6.98% to $48.8 billion in 2024, then rose by 1.78% to $49.7 billion in 2025.
  • Its Common Equity was $49.7 billion in Q4 2025, compared to $48.4 billion in Q3 2025 and $47.4 billion in Q2 2025.